Use is restricted to qualified researchers operating in certified laboratory environments
The segment is currently dominated by Eli Lilly's weight loss molecule Mounjaro (tirzepatide), which holds about 79% share, while Novo's semaglutide accounts for around 21% as of February-end
Arch Pharm Res 35(5):905910 Song X, He J, Xu H, Hu XP, Wu XL, Wu HQ, Liu LZ, Liao CH, Zeng Y, Li Y, Hao Y, Xu CS, Fan L, Zhang J, Zhang HJ, He ZD (2016) The antiviral effects of acteoside and the underlying IFN--inducing action
Results take consistent use, often several weeks, alongside balanced eating, exercise, and sleep
Monnier, and A
Food and Drug Administration and the European Medicines Agency, and until such approvals are granted for specific indications, orforglipron should be described as investigational rather than as an approved therapy for obesity, type 2 diabetes, or anything else